It is worth noting that Rapa has been reported to protect against neuronal death in PD animal models generated from treatment with neurotoxins such MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-OHDA (6-hydroxydopamine), and to preventL-DOPA (L-3,4-dihydroxyphenylalanine)-induced dyskinesia in 6-OHDA lesioned animals (Malagelada et al., 2010; Feyder et al., 2011). This evidence concerns the gene TRERF1 and Parkinson disease.